<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299415</url>
  </required_header>
  <id_info>
    <org_study_id>CASA404A2113</org_study_id>
    <nct_id>NCT01299415</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor</brief_title>
  <official_title>A Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effects of Fluvoxamine on the Pharmacokinetics of ASA404 in Adult Patients With Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This trial is designed to study the drug-drug interaction between ASA404 and fluvoxamine, an
      inhibitor of its metabolic pathway (CYP1A2). The study will consist of two phases. The
      purpose of the Core Phase is to study the drug drug interaction between fluvoxamine and
      ASA404. The purpose of the Extension Phase is to provide continued treatment for those
      patients that have not progressed during the Core Phase and to collect safety data on ASA404
      when given in combination with paclitaxel, docetaxel or the paclitaxel plus carboplatin
      chemotherapy regimen.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2009</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the effect of administration of fluvoxamine, a CYP1A2 inhibitor, after 2-cycles of ASA404, on the pharmacokinetics of ASA404</measure>
    <time_frame>approximately 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the effect of administration of fluvoxamine on the safety profile (incidence of AEs or SAEs generated) of ASA404</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the safety (incidence of AEs and SAEs) of ASA404 in combination with paclitaxel, doctaxel or the paclitaxel plus carboplatin chemotherapy regimen in patients with solid tumor malignancies</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ASA404 + Fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vadimezan™</intervention_name>
    <arm_group_label>ASA404 + Fluvoxamine</arm_group_label>
    <other_name>ASA404</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients having a histologically-proven and radiologically-confirmed advanced or
             metastatic solid tumor.

          2. WHO Performance Status of 0-2.

          3. A minimum of 4 weeks must have elapsed since the last treatment with other cancer
             therapies.

          4. Laboratory values within the ranges, as defined below:

               -  ANC ≥ 1.5 X 109 /L

               -  Platelets ≥ 100 X 109 /L

               -  Hemoglobin ≥ 10 g/dL

               -  Serum total bilirubin is within normal range

        Exclusion Criteria:

          1. Patients having CNS metastasis or evidence of leptomeningeal disease.

          2. Patients with any of the following:

               -  any clinical or electrocardiographic evidence of cadiac ischemia

               -  poorly controlled hypertension

               -  family history of unexplained sudden death

               -  long QT syndrome

               -  history of ventricular fibrillation or torsade de pointes

               -  congestive heart failure (NYHA class III or IV)

               -  myocardial infarction within 12 months of starting study treatment

          3. History of neuroendocrine tumors (e.g. carcinoid tumor, pancreatic islet cell tumor).

          4. Significant neurological or psychiatric disorder.

          5. Smokers (use of cigarettes within the last 3 months).

          6. Concomitant use of drugs that are associated with QTc interval prolongation or have a
             risk of causing torsade de pointes.

          7. Concomitant use of serotonin reuptake inhibitors (SSRIs), 5-hydroxytryptamine (5-HT)
             receptor agonists or selective serotonin / nor-epinephrine reuptake inhibitors (SNRIs)
             within 30 days prior to starting study treatment.

          8. Concomitant use of somatostain analogues (i.e. octreotide, lanreotide within 30 days
             prior to starting study treatment.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. of Indiana School of Medicine/Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center/ Clinical Trials Office</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine/Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASA404,</keyword>
  <keyword>Phase I,</keyword>
  <keyword>Oncology,</keyword>
  <keyword>CYP1A2,</keyword>
  <keyword>fluvoxamine,</keyword>
  <keyword>drug drug interaction,</keyword>
  <keyword>Novartis,</keyword>
  <keyword>Antisoma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>Vadimezan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

